UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant.
Get the full story...
A new study shows that certain genes are turned off early, before clinical signs of the disease appear, in the development of chronic leukemia.
Get the full story...
In many types of cancer, parts of the genetic material of tumor cells are switched off by chemical labels called methyl groups. This kind of methyl labeling ranges among the epigenetic changes that do not change the sequence of DNA building blocks. Such labels are found particularly often in genes which act as important inhibitors of pathogenic cell growth.
Get the full story...
Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).
Get the full story...
Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 50th Annual Meeting of the American Hematological Society.
Get the full story...
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL).
Get the full story...
Blocking the signals from a protein that activates cells in the immune system could help kill cells that cause a rare form of blood cancer, according to physicists and oncologists who combined computer modeling and molecular biology in their discovery.
Get the full story...
Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.
Get the full story...
Nearly a third of leukemia patients do not respond to chemotherapy, but this is not usually discovered until they have already endured a week-long chemotherapy treatment and waited a month to see whether it has worked. A new study shows that PET scans could tell how well a patient is responding after just one day of chemotherapy.
Get the full story...
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
Get the full story...
Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in the June 9 issue of Cancer Cell.
Get the full story...
Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).
Get the full story...